Abstract

BackgroundFibroblast growth factor receptor 2 (Fgfr2) deletion from murine peri-Wolffian duct stroma (ST) results in aberrant ureteric bud induction, abnormal ureteral insertion into the bladder, and high rates of vesicoureteral reflux (VUR). It is unclear which receptor docking protein(s) is/are responsible for Fgfr2 actions in these tissues. We investigated whether the docking protein, fibroblast receptor substrate 2α (Frs2α), had roles in peri-Wolffian duct stroma similar to Fgfr2.MethodsWe conditionally deleted Frs2α in per-Wolffian duct stroma with a Tbx18cre mouse line (Frs2αST−/−). We assessed for ureteric induction defects and alterations in downstream targets mediating defects. We performed euthanized cystograms and assessed ureter-bladder junctions via three dimensional (3D) reconstructions.ResultsEmbryonic day (E) 11.5 Frs2αST−/− embryos had many displaced ureteric bud induction sites versus controls. E11.0 Frs2αST−/− embryos had decreased Bmp4 expression and signaling, which can cause abnormal ureteric bud induction. Postnatal day 1 (P1) and P30 Frs2αST−/− mice had higher VUR rates and grades versus controls. Mutant refluxing ureters inserted improperly into the bladder and had shortened intravesicular tunnels versus controls:ConclusionsFrs2αST−/− have aberrant ureteric induction sites, improper ureteral insertion, shortened intravesicular lengths and VUR. Induction site defects appear secondary to reduced Bmp4 expression, similar to Fgfr2 mutants.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.